Development of Antibody-Directed Therapies: Quo Vadis?
- PMID: 29341367
- PMCID: PMC5838556
- DOI: 10.1002/anie.201712185
Development of Antibody-Directed Therapies: Quo Vadis?
Abstract
Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
Keywords: anti-tumor agents; antibody-drug conjugates; bioconjugation; drug delivery; linkers.
© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Atkins J. H., Gershell L. J., Nat. Rev. Drug Discovery 2002, 1, 491–492. - PubMed
-
- None
-
- Beck A., Goetsch L., Dumontet C., Corvaia N., Nat. Rev. Drug Discovery 2017, 16, 315–337; - PubMed
-
- Beck A., Haeuw J. F., Wurch T., Goetsch L., Bailly C., Corvaia N., Discovery Med. 2010, 10, 329–339. - PubMed
-
- Krall N., da Cruz F. P., Boutureira O., Bernardes G. J., Nat. Chem. 2016, 8, 103–113. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources